Use of anti-embryonic epsilon hemoglobin antibodies to identify fetal cells
AssigneeApplied Imaging Corporation
InventorMitchell Golbus
Life of this patent
Estimating the term…
Loading patent…
AssigneeApplied Imaging Corporation
InventorMitchell Golbus
Estimating the term…
An in vitro method of identifying or isolating fetal cells from a blood sample is described. Fetal nucleated erythrocytes or erythroblasts are identified by using an antibody or antibody fragment specific for embryonic hemoglobin or an embryonic hemoglobin chain. Once the fetal cells are identified, they can be treated to render the fetal nucleic acids or proteins available for identification or amplification. Detecting the occurrence or existence of selected fetal nucleic acids or proteins allows a quantitative or qualitative diagnostic or prenatal evaluation, including determining the sex of the fetus, determining chromosomal, single gene or protein abnormalities, and determining the presence or absence of particular genes, nucleic acid sequences or proteins.
A method of identifying a fetal erythrocyte or erythroblast cell in a blood sample from a pregnant female from 9 to 22 menstrual weeks, the method comprising:
Dependencies are inferred from the claim text.
Drawings are temporarily unavailable. Open the PDF at USPTO
No related US applications are recorded in the indexed filing history.
The carrier being a biological cell or cell fragment, e.g. bacteria, yeast cells: red blood cell
For microorganisms, e.g. protozoa, bacteria, viruses: animal cells
Involving proteins, peptides or amino acids: related to pregnancy or the gonads
Detection or diagnosis of diseases: gynecology or obstetrics
Term ended 25 Sep 2018 (estimated)
USPTO file history isn’t available for this patent, so only indexed dates are shown.
This invention relates to a method for separating and recognizing fetal cells from a blood sample. More particularly, it relates to the isolation and recognition of fetal nucleated erythrocytes or erythroblasts from maternal cells in a blood sample from a pregnant woman.
Fetal tissue, and in particular fetal DNA and chromosomes, is routinely used in prenatal diagnosis and other medical procedures that require an accurate assessment of the genome of the fetus. Currently, the fetal tissue is obtained by the use of amniocentesis, chorionic villus sampling (CVS), fetoscopy, or cordocentesis, as described in Thompson and Thompson Genetics in Medicine, 5th Edition, W. B. Saunders Co., Philadelphia, 1991.
In amniocentesis, a sample of amniotic fluid, which contains fetal cells, is transabdominally removed from the mother with a needle and syringe. Amniocentesis has inherent associated risks. The major risk is induction of miscarriage which is estimated to occur in 1 in 200 amniocenteses. Other risks include maternal infection and physical damage to the fetus. In CVS, trophoblast tissue is aspirated from the villous area of the chorion transcervically or transabdominally. The rate of fetal loss by this method may be as high as 1 in 100. Cordocentesis or percutaneous umbilical blood sampling provides a method of obtaining fetal blood directly from the umbilical cord with ultrasonic guidance. Each of these invasive methods carries risks to both the mother and the fetus.
The following example is provided merely for the purposes of illustration and are not to be construed in any way as limiting the scope of the present invention. Those skilled in the art will recognize that certain variations and modifications can be practiced within the scope of the invention.
Wedge smears were prepared from 14-week gestation abortus cord blood, whole blood from the mother (post-abortion), and a 1:25 mixture of the above cord blood into the maternal blood sample. The smears were fan dried for about half hour at room temperature, fixed in 100% methanol at -20.degree. C. for 10 minutes, and then in 100% acetone for 10 minutes at -20.degree. C.
The slides were then washed in PBS (10 mM Phosphate Buffered Saline (pH 7.4) for 5 minutes at room temperature with moderate agitation and fixed in 2% formaldehyde/PBS at room temperature for 10 minutes with moderate agitation. After washing the slides twice in PBS for 5 minutes at room temperature with moderate agitation, the slides were washed twice in TBS (100 mM Tris-HCl pH 7.6) for 5 minutes at room temperature with moderate agitation.